Published in N Engl J Med on November 30, 2017
Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017) 0.75
Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017) 4.42
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract (2009) 0.91
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. Eur J Endocrinol (2014) 0.82
Should dietary SFA be exchanged for linoleic acid? Am J Clin Nutr (2012) 0.75
Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556. Diabetes Care (2019) 0.75
Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients. Pancreas (2017) 0.75